We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a specialty company focused on developing and selling medications for central nervous system (CNS) diseases, including epilepsy, migraine ...

Supernus Pharmaceuticals stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial, sending its share into a tailspin. The stock was down nearly ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on its future.

The Cerebral Palsy market has demonstrated substantial growth in recent years, driven by increasing awareness, improved ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...